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Over the past few decades, obesity has become a global
epidemic and represents a major challenge for current and
future health.1 Although the pathogenesis of atrial ﬁbrillation
(AF) is not completely understood, there is compelling
evidence that obesity increases the risk for new-onset and
recurrences of AF and increases progression to more
persistent forms of AF.2 Weight reduction in patients with
AF reduces the burden and number of AF-episodes and
cumulative AF duration.3 These ﬁndings support therapy
directed at reducing weight and controlling risk factors in the
treatment of AF. We present the case of a 46-year-old male
patient with symptomatic AF and a temporal relation
between weight changes and recurrences of AF.Case report
A 46-year-old Caucasian male patient with a history of
hypertension and 10 years paroxysmal AF was referred to
our center. Treatment with class IC and III antiarrhythmic
drugs had failed, and the patient experienced progressive
frequency and severity of palpitations and fatigue (European
Heart Rhythm Association score ¼ 3). The calculated
CHA2DS2-VASc (acronym for congestive heart failure,
hypertension, ageZ75 y [double points], diabetes mellitus,
prior stroke or thromboembolism [double points], vascular
disease, age 65–74 years, sex category) score was 1 (hyper-
tension). The patient’s body mass index was 28.3 kg/m2 (97
kg, 185 cm) at time of referral. In the workup for pulmonary
vein isolation (PVI), transthoracic echocardiography results
showed normal cardiac function, and a left atrial volume
indexed of 29.1 mL/m2. The transcatheter PVI using radio-
frequency energy was performed. After the PVI, the patientKEYWORDS Atrial ﬁbrillation; Obesity; Risk factors; Pulmonary vein isolation
ABBREVIATIONS AF¼ atrial fibrillation; PVI¼ pulmonary vein isolation;
SR ¼ sinus rhythm (Heart Rhythm Case Reports 2015;1:342–344)
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).lost 10 kg with the help of our institutional patient-tailored 3-
month cardiac rehabilitation program, which constituted
low-intensity exercise guided by a physiotherapist, a bal-
anced diet supported by our institutional nutritionist, and
nutritional psychoeducation provided by a psychologist.
Thereafter, the patient was free of atrial arrhythmias during
the ﬁrst 6 months. In the next 6 months, the patient lost
another 4 kg, arriving at 83 kg. The variance in the patient’s
weight over time is depicted in Figure 1. Two years after the
ﬁrst PVI, the patient regained weight up to 98 kg and
experienced a symptomatic recurrence of paroxysmal AF,
which was conﬁrmed by 24-hour Holter monitoring. A
second electrophysiological examination and PVI were
scheduled, but with physical exercise the patient managed
to lose weight to 89 kg. From that point, he was asympto-
matic and in sinus rhythm. The re-PVI was therefore not
performed. The patient was in sinus rhythm for over 1 year,
until he regained weight up to a total of 100 kg. This time, the
recurrent AF episode was classiﬁed as persistent, which was
conﬁrmed by 24-hour Holter monitoring. The patient under-
went elective electrocardioversion, and ﬂecainide was
restarted. Another year later, weighing 103 kg, the patient
continued to have severely symptomatic AF, with an AF
burden on 24-hour Holter monitoring of 39%. The patient
was again referred to our cardiac rehabilitation facility; the
patient lost 15 kg again, and symptomatic AF disappeared.
Since then, neither AF nor other atrial arrhythmias have been
seen on 24-hour Holter monitoring.Discussion
Obesity is associated with multiple cardiovascular risk
factors, for example, hypertension, dyslipidemia, insulin
resistance, obstructive sleep apnea syndrome, pericardial
fat deposition, and a systemic inﬂammatory state.4 After
adjustment for other risk factors, obesity and is associated
with an increased risk of cardiovascular diseases, such as
ischemic heart diseases, heart failure, and AF.5 There is
abundant evidence for the involvement of obesity in the
development of AF. Obese individuals have up to 2.4-fold
increased risk for new-onset AF.6 The dynamic associationpen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Weight reduction and lifestyle management are
important in the treatment of symptomatic atrial
ﬁbrillation.
 Strict weight management using a cardiac
rehabilitation program is a treatment option for
obese patients before invasive treatment
modalities are deployed.
343de Maat et al A Case of Weight-Related Symptomatic Atrial Fibrillationof weight with AF prevalence was previously presented in
the Women's Health Study.7 Mechanisms underlying the
relation between obesity and new-onset AF, may relate to
structural remodeling caused by elevated end-diastolic
pressure, inﬂammation, and increased plasma volume.8,9
Also, obesity is known to be associated with sleep apnea
syndrome, an independent risk factor for AF.10
Our case underscores the direct (12-year) temporal
relation between weight and symptomatic AF. In this
particular case, when weight was 495 kg, the patient
experienced symptomatic AF recurrences. All 24-hour
electrocardiogram registrations performed, in total 360
hours’ worth, are depicted in Figure 1. After testing, no
obesity-associated comorbidities, such as diabetes, metabolic
syndrome, and sleep apnea syndrome, appeared to be present
in our case.
The ﬁnding that obesity itself may also induce AF or
increase AF burden has been reported in previous studies.11
It is unknown whether this risk factor is attributable only to
body composition or also to the level of physical activity.12
Also, the role of epicardial fat remains to be thoroughly
investigated as a risk factor.13 Obesity is a modiﬁable risk
factor, although its management can be very challenging in
clinical practice. A recent randomized trial compared inter-
vention with active weight management to modiﬁcation with
general lifestyle advice. Results of this pivotal paper showFigure 1 Association between weight and heart rhythm. AF ¼ atrial
ﬁbrillation; PVI ¼ pulmonary vein isolation; SR ¼ sinus rhythm.that weight reduction with intensive risk-factor management
causes a signiﬁcant reduction in AF symptom burden and
severity.3 The recent ARREST-AF trial showed that aggres-
sive risk-factor management improves long-term outcomes
of AF ablation.14 Furthermore, if this weight loss is sustained
at long-term follow-up, reduction of AF burden and main-
tenance of sinus rhythm are signiﬁcantly higher compared to
those in patients with weight ﬂuctuation.15 In fact, our case
nicely illustrates the relation of overweight and recurrence of
symptomatic AF, and it stresses the importance of weight
counseling in patients referred for symptomatic AF, espe-
cially before considering invasive treatment modalities such
as transcatheter or surgical PVI. A cardiac rehabilitation
program is an option for such patients.
Conclusions
Weight reduction and lifestyle management are important in
the treatment of symptomatic AF and warrant more attention.
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